Fig. 6: CEBPD mediates SOX2, OCT4, NANOG, and ABCA1 upregulation in TMZ-treated GBM cells. | Cell Death Discovery

Fig. 6: CEBPD mediates SOX2, OCT4, NANOG, and ABCA1 upregulation in TMZ-treated GBM cells.

From: CCAAT/Enhancer-binding protein delta mediates glioma stem-like cell enrichment and ATP-binding cassette transporter ABCA1 activation for temozolomide resistance in glioblastoma

Fig. 6

A The expression of CEBPD, SOX2, OCT4, NANOG, and ABCA1 is increased in TMZ-treated U87MG cells. Monolayer U87MG cells were treated with 50 μM TMZ for 6 h (for RNA) or 24 h (for protein). Total RNA and total protein lysates were harvested, and then, the SOX2, OCT4, NANOG, and ABCA1 transcription and expression levels were assessed by RT-qPCR and western blot. B Knockdown of CEBPD downregulates SOX2, OCT4, NANOG, and ABCA1 transcripts in TMZ-treated GBM cells. Knockdown of CEBPD was conducted in U87MG stable cells with IPTG for 48 h, and then, the cells were treated with 50 μM TMZ for 6 h. Total RNA was harvested, and the CEBPD, SOX2, OCT4, NANOG, and ABCA1 expression levels were assessed by RT-qPCR. The summary data are presented as the mean ± SEM; the numbers in the bars represent the sample sizes; one-way ANOVA and Student’s t-test; *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page